User profiles for JWC Alffenaar

Johannes Alffenaar

Verified email at sydney.edu.au
Cited by 14964

[HTML][HTML] Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

MH Abdul-Aziz, JWC Alffenaar, M Bassetti… - Intensive care …, 2020 - Springer
Purpose This Position Paper aims to review and discuss the available data on therapeutic
drug monitoring (TDM) of antibacterials, antifungals and antivirals in critically ill adult patients …

Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents

RJM Brüggemann, JWC Alffenaar… - Clinical Infectious …, 2009 - academic.oup.com
There are currently a number of licensed azole antifungal drugs; however; only 4 (namely,
fluconazole, itraconazole, posaconazole, and voriconazole) are used frequently in a clinical …

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

N Ahmad, SD Ahuja, OW Akkerman, JWC Alffenaar… - The Lancet, 2018 - thelancet.com
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs, …

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

…, R Centis, L D'Ambrosio, JWC Alffenaar… - European …, 2012 - Eur Respiratory Soc
Linezolid is used off-label to treat multidrug-resistant tuberculosis (MDR-TB) in absence of
systematic evidence. We performed a systematic review and meta-analysis on efficacy, safety …

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement

C Lange, I Abubakar, JWC Alffenaar, G Bothamley… - 2014 - Eur Respiratory Soc
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis
(TB) substantially challenges TB control, especially in the European Region of the World …

Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot–based methods for …

…, DJ Touw, CP Stove, JWC Alffenaar - Therapeutic Drug …, 2019 - journals.lww.com
Dried blood spot (DBS) analysis has been introduced more and more into clinical practice to
facilitate Therapeutic Drug Monitoring (TDM). To assure the quality of bioanalytical methods…

Determination of moxifloxacin in dried blood spots using LC–MS/MS and the impact of the hematocrit and blood volume

DH Vu, RA Koster, JWC Alffenaar, J Brouwers… - … of Chromatography B, 2011 - Elsevier
Moxifloxacin (MFX) is a potential oral agent use in the treatment of multidrug-resistance
tuberculosis (MDR-TB). Due to variability in pharmacokinetics and in vitro susceptibility of …

Bedaquiline resistance: its emergence, mechanism, and prevention

…, TVA Nguyen, DH Vu, JWC Alffenaar - Clinical Infectious …, 2018 - academic.oup.com
Bedaquiline, a new antituberculosis drug, has already been used in >50 countries. The
emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this new …

[HTML][HTML] Therapeutic drug monitoring of posaconazole: an update

…, A Veringa, LFR Span, JWC Alffenaar - Current fungal infection …, 2016 - Springer
Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity.
In addition to the oral suspension, a delayed-release tablet and intravenous formulation …

Voriconazole metabolism is influenced by severe inflammation: a prospective study

…, TS van der Werf, JWC Alffenaar - Journal of …, 2016 - academic.oup.com
Background During an infection or inflammation, several drug-metabolizing enzymes in the
liver are down-regulated, including cytochrome P450 iso-enzymes. Since voriconazole is …